New data suggests Covaxin generates robust memory to Covid-19 and variants six months after vaccination

Effectiveness of Covaxin against the Omicron variant is currently being studied

Six benefits of Cloud Computing in the pharma industry

Samsung Biologics expands tie-up with AstraZeneca to include cancer therapy

The company will manufacture a cancer immunotherapy product from 2022

USFDA authorises Astra’s antibody cocktail to prevent Covid

Evusheld is a combination of two long-acting monoclonal antibodies and is the only antibody therapy authorised in the US to prevent Covid-19

B Medical Systems to invest Rs 100 cr. to manufacture medical cold chain equipment in Gujarat

An MoU was signed between B Medical Systems and Gujarat government recently

Roche develops tests to identify Omicron variant

Roche subsidiary TIB Molbiol rapidly developed additional testing options to differentiate mutations in the Omicron SARS-CoV-2 variant, as they continue to offer new and accurate detection solutions

Monthly production capacity of Covishield and Covaxin touches 90% : Govt

Serum has a capacity of 250-275 million whereas Bharat Biotech has a capacity of 50-60 million

Booster dose for those above 40

The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19

Serum seeks DCGI approval for booster dose in India

The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India

ZyCoV-D to be initially administered in seven states

The three doses of ZyCoV-D are to be administered 28 days apart. The vaccine was given emergency use authorisation (EUA) by the Indian drug regulator on August 20